US 11,951,086 B2
Tablet or composition having n-acyl ethanolamine and cannabinoid
Debra Kimless, Chadds Ford, PA (US); John S. Althaus, Saline, MI (US); and Stephen Goldner, West Bloomfield, MI (US)
Assigned to PURE GREEN PHARMACEUTICALS, INC., West Bloomfield, MI (US)
Appl. No. 17/044,521
Filed by PURE GREEN PHARMACEUTICALS, INC., West Bloomfield, MI (US)
PCT Filed Apr. 3, 2019, PCT No. PCT/US2019/025476
§ 371(c)(1), (2) Date Oct. 1, 2020,
PCT Pub. No. WO2019/195355, PCT Pub. Date Oct. 10, 2019.
Claims priority of provisional application 62/651,775, filed on Apr. 3, 2018.
Prior Publication US 2021/0015774 A1, Jan. 21, 2021
Int. Cl. A61K 31/192 (2006.01); A61K 9/107 (2006.01); A61K 9/20 (2006.01); A61K 31/01 (2006.01); A61K 31/16 (2006.01); A61P 29/02 (2006.01)
CPC A61K 31/192 (2013.01) [A61K 9/107 (2013.01); A61K 9/20 (2013.01); A61K 31/01 (2013.01); A61K 31/16 (2013.01); A61P 29/02 (2018.01)] 18 Claims
OG exemplary drawing
 
1. A composition comprising:
n-acyl ethanolamine;
at least one cannabinoid; and
at least one terpene, wherein the n-acyl ethanolamine is in the form of lyophilized, dry preassembled micelles, and the at least one cannabinoid is entrapped in the micelles.